Novartis files Form 6-K with 2025 annual reports

Q: What does Novartis (NVS) report in this Form 6-K?

Novartis uses this Form 6-K to furnish its Annual Report 2025 and a separate Report on Nonfinancial Matters 2025 as exhibits, making these key disclosure documents available to U.S. investors and regulators.

Q: Which documents are attached to the Novartis (NVS) Form 6-K?

The Form 6-K lists two exhibits: Exhibit 99.1, Annual Report 2025, and Exhibit 99.2, Report on Nonfinancial Matters 2025. These exhibits together cover the company’s annual and nonfinancial disclosures for 2025.

Q: Why did Novartis (NVS) file this Form 6-K as a foreign private issuer?

Novartis filed this Form 6-K as a foreign private issuer to transmit its 2025 annual and nonfinancial reports under U.S. securities rules, ensuring its key disclosures are formally available to investors in the United States.

Q: Who signed the Novartis (NVS) Form 6-K dated February 4, 2026?

The Form 6-K was signed for Novartis by Paul Penepent, who is identified as Head Financial Reporting and Accounting, confirming the company’s authorization of this submission under the Securities Exchange Act of 1934.

Q: What is the filing date and address listed for Novartis (NVS) in this Form 6-K?

The report on Form 6-K is dated February 4, 2026. Novartis lists its principal executive offices at Lichtstrasse 35, 4056 Basel, Switzerland, reflecting its main corporate location as a foreign private issuer.

Novartis furnished a report on Form 6-K that provides investors with access to its latest annual information.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

Novartis furnished a report on Form 6-K that provides investors with access to its latest annual information. The filing submits the Novartis Annual Report 2025 and the Report on Nonfinancial Matters 2025 as exhibits, making these documents officially available under U.S. securities law for foreign private issuers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Novartis (NVS) report in this Form 6-K?

Novartis uses this Form 6-K to furnish its Annual Report 2025 and a separate Report on Nonfinancial Matters 2025 as exhibits, making these key disclosure documents available to U.S. investors and regulators.

Which documents are attached to the Novartis (NVS) Form 6-K?

The Form 6-K lists two exhibits: Exhibit 99.1, Annual Report 2025, and Exhibit 99.2, Report on Nonfinancial Matters 2025. These exhibits together cover the company’s annual and nonfinancial disclosures for 2025.

Why did Novartis (NVS) file this Form 6-K as a foreign private issuer?

Novartis filed this Form 6-K as a foreign private issuer to transmit its 2025 annual and nonfinancial reports under U.S. securities rules, ensuring its key disclosures are formally available to investors in the United States.

Who signed the Novartis (NVS) Form 6-K dated February 4, 2026?

The Form 6-K was signed for Novartis by Paul Penepent, who is identified as Head Financial Reporting and Accounting, confirming the company’s authorization of this submission under the Securities Exchange Act of 1934.

What is the filing date and address listed for Novartis (NVS) in this Form 6-K?

The report on Form 6-K is dated February 4, 2026. Novartis lists its principal executive offices at Lichtstrasse 35, 4056 Basel, Switzerland, reflecting its main corporate location as a foreign private issuer.

Does the Novartis (NVS) Form 6-K include detailed financial tables in the main text?

The main text of this Form 6-K does not contain financial tables. Instead, it identifies and transmits the Annual Report 2025 and Report on Nonfinancial Matters 2025 as separate attached exhibits where detailed information is provided.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/04/2026 - 06:52 AM EST

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 or 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

Report on Form 6-K dated February 4, 2026

(Commission File No. 1-15024)

Novartis AG

(Name of Registrant)

Lichtstrasse 35

4056 Basel

Switzerland

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F: ☒

Form 40-F: ☐

Exhibits:

99.1 Annual Report 2025

99.2 Report on Nonfinancial Matters 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Novartis AG


Date: February 4, 2026	By:	/s/ PAUL PENEPENT

	Name:		Paul Penepent
	Title:		Head Financial Reporting and Accounting

Source: View Original Filing on SEC EDGAR